sofidexFor patientsAre you a clinician? Clinical site

Health Library  ›  News  ›  Health Drive  ›  The aspirin advice changed. Did anyone tell you?

The aspirin advice changed. Did anyone tell you?

For a generation, a daily aspirin was what careful people did. Three big trials ended that — unless you have already had a heart attack, in which case nothing changed at all.

Health Drive

The aspirin advice changed. Did anyone tell you?

0:0027:45

Transcript

Welcome to the sofidex Health Drive podcast series. Today we are talking about the daily aspirin. The small tablet half a generation was told to take for their heart, and the advice that quietly reversed while most of the people taking it were not looking. Maybe there is one in your pill organiser right now. Maybe a parent takes one, because a doctor suggested it years ago, or because their own father died young and it felt like doing something. And maybe you have seen a headline saying it changed, and wondered whether anybody was going to tell you directly.

And the answers on offer come in the usual two unhelpful sizes. Either aspirin is a harmless little habit, practically a vitamin, or it is suddenly dangerous and you should stop today. Neither of those tells you what to do with the tablet in your own kitchen. So we want to ask the question properly. Not whether aspirin works, because for some people it clearly does. The question is which people, who actually got measured, and why the answer splits cleanly in two.

We will follow one woman, eleven years into the habit, from the morning a new doctor told her to stop. Along the way: where the habit came from, the three big trials that ended it, and the one group of people for whom nothing changed at all. That last part is the most important sentence in the episode. And to say it before the worry grows: nothing in tonight's story is an emergency. Nobody needs to flush anything this evening. The whole episode funnels into one ten-minute conversation, and we will tell you exactly which question to bring to it.

One thing before we start. This is health information, not medical advice, and nothing in it is a substitute for talking to your own doctor about your own treatment. What we can tell you is where all of it came from — 7 published sources, all listed with the episode. I want to do this one through a single person again. Somebody we invent, so nobody's privacy is on the line. Call her Ruth. She's sixty-eight. And every morning for eleven years she's taken one small aspirin with her tea. Her father died of a heart attack at sixty. Her old doctor said the aspirin couldn't hurt. And last month a new doctor looked at her list and said, quite casually, you can stop that now. She hasn't stopped. She's rattled.

And she's earned the right to be rattled. Because think about what she's actually been told. For eleven years, this protects you. Then one Tuesday, actually, it might be hurting you. Same tablet. Same woman. And nobody sat her down and explained what changed. That's the real failure here. The advice moved, and the explanation never arrived. So that's today's job. Not to tell Ruth what to do. To show her what the people who changed the advice were looking at when they changed it.

Okay. Start at the beginning, then. Why was half a generation told to take a daily aspirin in the first place? Because that habit came from somewhere.

Well, it came from a genuinely great result. And the logic is worth laying out, because the logic is where the trouble hides. Because a heart attack is a clot. A plaque in an artery cracks, platelets pile onto the crack, and the pile blocks the pipe. And aspirin makes platelets less sticky. Less sticky, smaller pile. Fewer blocked pipes. And in people who've already had a heart attack or a stroke, that works. Not subtly. Properly.

You say properly. I'd like the number, because this episode is going to turn on numbers.

Then here it is. There's a huge pooled analysis from 2009, the Antithrombotic Trialists' Collaboration. It gathered the trials of aspirin in people who already had vascular disease. Sixteen trials. Seventeen thousand people. In the secondary prevention trials, aspirin cut serious vascular events from 8.2 to 6.7 per cent per year. So: roughly one event prevented each year for every seventy such people. Every year. For a tablet costing pennies. That result isn't in dispute. It wasn't then. And it isn't now.

Right. So for people who've had the heart attack, aspirin works. And then somebody made a leap.

The most natural leap in medicine. If it prevents the second heart attack, surely it prevents the first. Same arteries. Same platelets. Same clot. And on that logic, aspirin quietly spread from the cardiac ward to the medicine cabinet. So doctors suggested it. Magazines blessed it. People like Ruth's father died young, and people like Ruth reached for something. One small tablet. And it felt like prudence. And for decades, taking it was simply what careful people did.

But the leap skipped a step. That's where you're going.

And it skipped the step this whole episode lives in. Because Ruth isn't her father. Because he'd had angina for years. His arteries had declared themselves. Hers never have. And she's what the trade calls primary prevention. Preventing the first event, in someone with no vascular disease. And in primary prevention, the arithmetic changes completely. Not because aspirin stops working. Because the thing it prevents gets rare, while the harm it causes doesn't.

Say that again, slowly. Because I think that's the sentence most people have never heard.

Aspirin's benefit scales with your risk. But its harm doesn't care. Because the bleeding comes along at roughly the same rate whether you were ever going to have a heart attack or not. So in a man with a stent, the maths is lopsided in aspirin's favour. High chance of the thing it prevents. Same bleeding cost. But in a healthy sixty-eight-year-old woman, the heart attack it might prevent is already unlikely. And the bleed it might cause is just as likely as ever. Two scales. One weight shrinks. The other doesn't move.

And the harm itself. Before we drown in trial names, what does aspirin bleeding actually look like? Because a bleed sounds survivable. A bruise sounds like nothing.

Well, mostly it's the gut. The same stickiness that keeps platelets off a cracked plaque keeps them off the small erosions in your stomach lining, and aspirin irritates that lining directly too. So the classic event is a stomach or duodenal bleed. Sometimes slow. A creeping anaemia somebody catches on a blood test, a tiredness that got blamed on age for a year. Sometimes fast. Black stools, a collapse in the bathroom, a transfusion, an endoscopy on a Sunday night. And most people survive it. But it's a hospital admission, it's genuinely frightening, and in an eighty-year-old it can be the push that starts a longer slide. The frailty, the fear of food, the iron tablets. And then there's the rarer, worse one. Bleeding into the head. That's the one that turns up in these trials under the bland phrase haemorrhagic stroke, and it's every bit as bad as the stroke people take aspirin to avoid. So major bleeding, in these results, doesn't mean bruises. It means events in the same weight class as the heart attacks being prevented. Hold that in mind through everything that follows.

And the tablet itself. Ruth's box says 81 milligrams. You keep saying 100. Somebody listening is now worried they've been taking the wrong aspirin.

They haven't. And it's worth thirty seconds, because the numbers look stranger than they are. Low-dose aspirin means roughly 75 to 100 milligrams a day. And America standardised on 81, because the old baby aspirin was a quarter of the old adult tablet. And Europe mostly sells 75 or 100. And the big trials used 100 milligrams of enteric-coated aspirin, which sits in the same band. So there's no meaningful cliff between 81 and 100. One more thing while we're at the box. Coated, the enteric bit, means the tablet dissolves past the stomach. But it doesn't make aspirin safe for the stomach. Because most of the bleeding risk comes through the bloodstream, from the platelet effect itself, not from the tablet sitting on the stomach wall. So a coated tablet bleeds too. The trials that found the harm used the coated kind.

Okay. So the scales were always two kinds of disaster. Did the people doing the leaping know how close the scales sat? Or did it take a study?

They half knew. And that same 2009 analysis is the honest record of the half-knowing. Alongside the secondary trials, it pooled six primary prevention trials. Ninety-five thousand people with no vascular disease. And aspirin did work, in a thin sense. It produced a 12 per cent proportional reduction in serious vascular events. But look at the absolute terms. Events fell from 0.57 to 0.51 per cent per year. Six people helped, in ten thousand, per year. And major gut and other bleeds rose from 0.07 to 0.10 per cent per year. And the authors didn't hedge. They wrote that in primary prevention, aspirin is of uncertain net value. And they added a detail that should've stung more than it did. The main risk factors for coronary disease were also risk factors for bleeding. The people with the most to gain were the same people with the most to lose.

Uncertain net value. In 2009. And yet the tablets kept being taken for another decade. Why didn't the advice turn there?

Because uncertain isn't a headline. And because habits with a good origin story die hard. But there was also a real hope keeping the habit alive. Because aspirin had been linked to less bowel cancer over the long run, and for a while the official American advice leaned on that as part of the bargain. So the tablet had two stories working for it. Hearts now, bowels later. So what actually turned the advice was 2018. One year. Three big randomised trials, all in primary prevention, all reporting within months of each other. Different populations. Same shape of answer, three times. By the end of that year the question was basically settled, and the guidelines spent the next few years catching up. So let's take the three trials one at a time. Because Ruth is standing in one of them.

But why 2018? That's the bit I don't get. The doubt existed in 2009. Why did the decisive trials take another decade to arrive?

Because trials like these are enormous, slow and unprofitable. And think about what you're asking for. To measure a benefit of six people in ten thousand per year, you need tens of thousands of participants followed for five or more years. So that's hundreds of millions of dollars, spent to test a tablet that costs pennies and earns nobody anything. So the money had to come from governments mostly. ASPREE ran on the American National Institute on Aging, among others. And ASCEND leaned on the British Heart Foundation. And here's the detail I find genuinely persuasive. ARRIVE was funded by Bayer. The company that sells aspirin paid for a twelve-thousand-person trial of its own product, presumably hoping for a different answer. And it got nothing, and published the nothing. So when all three landed the same way inside one year, there wasn't anywhere left for the old advice to hide.

Go on, then. Trial one.

ARRIVE. Published in the Lancet in 2018. Over twelve thousand adults at moderate heart risk. Men fifty-five and over, women sixty and over, with risk factors. No diabetes. No previous heart disease. And one group got 100 milligrams of aspirin a day, the other a placebo, followed for a median of five years. And the result was nothing. The main cluster of bad outcomes happened in 4.29 per cent of the aspirin group and 4.48 per cent of the placebo group. Statistically, a coin toss. And gut bleeding, mostly mild, happened at twice the rate on aspirin. So the one effect the trial could actually demonstrate was the harm.

Hold on. Moderate risk. These were people with risk factors, chosen because something was likely to happen. And still nothing?

And the investigators noticed the same thing, because the event rate undershot their planning badly. Their own explanation is the most interesting sentence in the paper. The event rate was much lower than expected, probably reflecting contemporary risk management. So, translation: modern care had already defused these people. Statins. Blood pressure pills. Less smoking. The heart attacks aspirin was meant to prevent were already being prevented by other things. Aspirin turned up to a fire that was mostly out.

Which raises a thought I want to park and come back to. If the background changed, old aspirin evidence ages badly. But first, trial two.

ASCEND. Same year, New England Journal. And this one matters because it picked the hardest case for the sceptics. Diabetes. Over fifteen thousand adults who had diabetes but no evident cardiovascular disease. And diabetes raises heart risk substantially, so if primary prevention aspirin was going to shine anywhere, it was here. And it did work. Serious vascular events: 8.5 per cent on aspirin, 9.6 on placebo, over about seven years. Real benefit. But major bleeding went from 3.2 to 4.1 per cent. And the authors' own conclusion is the one Ruth should hear word for word. The absolute benefits were largely counterbalanced by the bleeding hazard.

One per cent helped. One per cent hurt. A wash. Even in diabetics.

Even there. And notice what kind of wash. Because the benefit was fewer heart attacks and strokes. But the cost was serious bleeding. Mostly from the gut. Some sight-threatening, into the eye. Some into the head. So you're not trading like for like. You're swapping one rare disaster for a different rare disaster. And when the numbers come out even, a tablet taken every day for years is doing a lot of work to achieve nothing.

Trial three. The one Ruth is standing in.

ASPREE. And it's the one that changed the temperature of this whole conversation. Nineteen thousand people, seventy and older, in Australia and the United States. Healthy. No heart disease, no dementia, no disability. Which is Ruth in two years, near enough. And the aspirin group took 100 milligrams, enteric-coated, daily. Median follow-up, 4.7 years. Cardiovascular events: 10.7 per thousand person-years on aspirin, 11.3 on placebo. No real difference. Major bleeding: 8.6 versus 6.2. Clearly worse. So in people Ruth's age, the trial couldn't find the benefit. But it had no trouble finding the harm.

And then there's the finding that made the newspapers. The deaths.

So, carefully, because this is the part that gets overstated. ASPREE published a separate paper on mortality. And death from any cause ran at 12.7 per thousand person-years on aspirin against 11.1 on placebo. Higher, on the tablet. And the excess was mostly cancer deaths. Cancer was the major contributor to the higher mortality. Now, the investigators themselves flagged this as strange. Because decades of work had hinted aspirin might protect against bowel cancer, remember. Not feed cancer deaths. So their own paper says the result was unexpected and should be interpreted with caution. And I'll say the same. So treat it as a question mark, not a verdict. But notice which way the question mark points. Nobody was debating whether aspirin was accidentally saving extra lives. The surprise was on the harm side.

So. Three trials, one year. Moderate risk, nothing. Diabetes, a wash. Over-seventies, harm with no benefit. And then the guideline moved.

In 2022. The US Preventive Services Task Force, the body that writes this kind of advice for America, formally reversed its position. Two lines matter. For adults sixty or older, it recommends against initiating low-dose aspirin for primary prevention. Full stop. That's a D recommendation, their way of saying the evidence points to no net benefit. And for adults forty to fifty-nine with at least a 10 per cent ten-year heart risk, it says the decision should be an individual one. And it adds, in writing, that the net benefit in this group is small. And notice what happened to the bowel cancer story, too. It quietly fell out of the bargain. Because the panel's own review called the cancer results less robust and highly variable. So the second story propping up the tablet went the same way as the first.

They didn't guess, presumably. What's under that recommendation?

Well, there's a published evidence report under it, and the totals are worth hearing once. Eleven randomised trials. All of the primary prevention evidence, pooled. Aspirin cut major cardiovascular events with an odds ratio of 0.90. A real reduction of about a tenth, tiny in absolute terms. But it raised major bleeding with an odds ratio of 1.44. And across all those people, aspirin wasn't significantly associated with lower cardiovascular mortality or lower all-cause mortality. Small benefit. Small harm. No lives demonstrably saved. That's the whole ledger.

One thing in that ledger needs unpacking. Stroke appears on both sides of it. Aspirin is supposed to prevent strokes. And you just told me bleeding into the head is a stroke. Both words are stroke.

And that confusion sits at the centre of this whole subject, so let's take it apart. Because a stroke is just brain damage from a blood vessel problem, and there are two opposite ways a vessel can fail. It can block. A clot lodges, blood stops, the territory downstream starves. That's an ischaemic stroke, the common kind, and it's the kind aspirin helps prevent, because aspirin fights clots. Or the vessel can burst. Blood where it shouldn't be, pressure on the brain. That's a haemorrhagic stroke. And a drug that fights clotting makes bursting worse, not better. So the same tablet pushes the two kinds of stroke in opposite directions. In somebody at high clotting risk, the trade goes your way. In somebody who was never likely to clot, you've bought protection you didn't need with a bleeding risk you didn't have. Which is Ruth's situation in one sentence.

Translate the odds ratios, though. Because 0.90 and 1.44 are exactly the kind of numbers this show keeps warning people about. Relative somethings, hiding the real size.

Right. And regular listeners will recognise this trick from our relative risk episode, because it's the same trap in reverse. Because an odds ratio of 0.90 sounds like a tenth off your heart attack. But a tenth off what? And the panel's review answered that in its own flat language. Small absolute risk reductions in cardiovascular events. Small absolute increases in major bleeding. The same word, small, on both pans of the scale. So: real, and tiny, and roughly matched. And that's the entire story of this episode in two digits. So whenever somebody sells you a percentage, make them tell you the before and the after. From what, to what. We did a whole episode on exactly that question, and this is it being used in anger.

Give me the scale of what's at stake, though. Because small per-person numbers times a whole country is still a lot of heart attacks.

It is, and that's why the panel agonised rather than shrugged. In the United States, roughly six hundred and five thousand people have a first heart attack each year. And about as many again have a first stroke. And that's the pool the old advice was trying to drain with a penny tablet. And a tenth off numbers like those would matter, if it were free. The whole point of the reversal is that it isn't free. But spread the same tablet across millions of low-risk people and the bleeds stack up in the same proportion. Population-sized benefit, population-sized harm, cancelling out. The arithmetic that failed for one Ruth fails identically for millions of her.

Okay. Now the turn. Because I know who's listening to this with their blood running cold. And it isn't Ruth. It's her brother.

Tom. Let's invent him too. Sixty-two. A stent in his right coronary artery since 2019, aspirin every morning since. And Tom hears a radio item saying the aspirin advice reversed, and he thinks, that's me, and flushes his tablets. Tom is the person this episode is most anxious about. Because nothing in anything I've said today applies to him. The reversal is about primary prevention. Starting aspirin in people whose arteries have never declared themselves. Tom's arteries have declared themselves. Because he has vascular disease. He's secondary prevention, the territory where that pooled analysis found the large, undisputed benefit. For Tom, aspirin isn't a habit. It's treatment.

So the single most dangerous reading of this episode is a stent patient hearing aspirin is over and stopping.

And it isn't a hypothetical reading. Because every time this story cycles through the news, doctors brace for it. The headline says aspirin reversed. The small print says for healthy people who never had a cardiac event. And headlines don't carry small print. So let me put it as bluntly as this show ever gets. If you've had a heart attack, a stroke, a stent, a bypass — if a doctor has ever told you that you have vascular disease — this episode's news is not your news. Don't stop your aspirin off the back of a podcast. Any question about your tablet belongs with your own doctor, who knows which group you're in.

Which brings us back to Ruth. No stent. No heart attack. No diagnosis. Just a dead father and eleven years of habit. What does the evidence actually say to her?

It says three things, and they're all gentler than she fears. First, the advice against starting is about starting. She's sixty-eight. If she walked in fresh today, nobody would put her on aspirin. And the guideline is explicit about the over-sixties. But she isn't starting. She's eleven years in, with, apparently, eleven years of not bleeding behind her. Second, that history matters. Because tolerating aspirin for a decade is information about her stomach and her particular risk. And third, stopping is a real decision with its own small print. Not a thing to do alone on a Tuesday because a podcast mentioned a trial.

Why not? That's the part that will surprise people. If the tablet isn't helping, surely you just stop.

Probably, for many people like her, stopping is exactly what her doctor will suggest. But it should be her doctor's suggestion, made while looking at her notes. Because here's what the doctor can see that a podcast can't. Why it was started. Whether there was ever a scan, a scare, a murmur of actual vascular disease in her records, which would move her to Tom's side of the line. What her current ten-year risk works out to, because there are calculators for exactly this, fed by her blood pressure and her cholesterol and her smoking history, and the answer changes the advice. What else she takes, because some drug pairings change bleeding risk. A conversation of about ten minutes. And the habit of eleven years either ends cleanly or continues deliberately. Either way, on purpose.

And what about her daughter? Forty-five, healthy, watching her mother go through this. Her grandfather died at sixty, remember. Is she supposed to start aspirin at some point, or is that era just over?

For her, the modern advice is a flowchart with one honest box. Probably not, and not without arithmetic. She's in the forty-to-fifty-nine window where the guideline says individual decision. But read what qualifies her for even that conversation. A ten-year cardiovascular risk of 10 per cent or more. A healthy forty-five-year-old woman is almost never near that number, family history or not. And even for the people who are, the panel's own wording is deflating. The net benefit is small. So the realistic version of her future isn't a quiet decision to copy her mother at fifty. It's a risk calculation with a professional, where the likely answer is work on blood pressure, lipids and smoking instead. The boring trio that actually moved the national numbers.

There's a version of Ruth who hears all this and feels cheated. Eleven years. Possibly for nothing. Possibly for a stomach bleed she narrowly didn't have. What do you say to her?

That she did nothing foolish. And neither, mostly, did her old doctor. The best reading of the old evidence genuinely supported the habit when the habit formed. What changed isn't that somebody caught an error. It's that the world moved. Statins arrived properly. Blood pressure treatment improved. Smoking collapsed. First heart attacks got rarer, so the tablet's job shrank, while its bleeding cost sat still. And then came the three big 2018 answers, and the balance was weighed honestly. That's not a scandal. That's the system working, slowly, in public. The scandal, if there is one, is that the people taking the tablet were the last to be told.

Which is itself a lesson about medical advice generally. The stuff that reverses isn't usually the stuff that was stupid.

Almost never. It's the extrapolations. The things that worked brilliantly in one group, stretched to a bigger group where nobody had measured. Aspirin after a heart attack was measured, and it held. Aspirin instead of a heart attack was borrowed logic. And borrowed logic is exactly the kind of advice a better experiment eventually calls in. So if you want a rule of thumb for which health advice will still be standing in twenty years, ask how close it stayed to the people it was tested on.

Let's land this. Monday morning. Ruth's kitchen, the tea, the tablet. What are the take-homes?

Three things. And they're all small. First, find out which group you're in. One question: have I ever actually had a cardiovascular event or diagnosis? Heart attack, stroke, stent, bypass. If yes, you're Tom. The reversal isn't about you. Keep taking it, and take your questions to your own doctor. Second, if you're Ruth — no event, no diagnosis, just the habit — don't panic and don't flush anything. This is a ten-minute conversation at your next appointment, not an emergency. The tablet you've tolerated for years won't ruin you this week. And third, if you're neither — if you're forty-five and healthy and wondering whether to start taking aspirin because your father did — the answer from the current evidence is, almost certainly, don't start. Not without a doctor working out your actual risk first. Because the era of aspirin as general-purpose prudence is over.

And the bigger take-home. The one above the tablet.

When health advice reverses, the first question is never who was wrong. It's who was measured. Find out whether you're in the group the new evidence describes. Most of the fear in Ruth's kitchen, and most of the danger in Tom's, comes from skipping that one question. The advice didn't betray anyone. It got more precise. And your job, with your doctor, is to work out where the precision puts you.

Three things to ask your doctor

  • Have I ever actually had a cardiovascular event or diagnosis — which side of this advice am I on?
  • I have been taking a daily aspirin for years and nobody told me to stop. Should I still be taking it?
  • What is my ten-year cardiovascular risk, and does it change what you would advise me about aspirin?

Sources

  1. 1Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1. PMID 19482214.In primary prevention, aspirin yielded a 12 percent proportional reduction in serious vascular events (0.51 versus 0.57 percent per year) but increased major bleeds, for uncertain net value; in secondary prevention the absolute benefit was far larger (6.7 versus 8.2 percent per year)
  2. 2Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 Sep 22;392(10152):1036-1046. doi:10.1016/S0140-6736(18)31924-X. PMID 30158069.In moderate-risk adults without diabetes, aspirin did not reduce the primary composite of cardiovascular events (4.29 versus 4.48 percent) and roughly doubled gastrointestinal bleeding
  3. 3ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi:10.1056/NEJMoa1804988. PMID 30146931.In adults with diabetes and no evident cardiovascular disease, aspirin reduced serious vascular events (8.5 versus 9.6 percent) but caused major bleeding (4.1 versus 3.2 percent), with absolute benefits largely counterbalanced by the bleeding hazard
  4. 4McNeil JJ, Wolfe R, Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi:10.1056/NEJMoa1805819. PMID 30221597.In healthy adults seventy and older, daily low-dose aspirin did not significantly lower cardiovascular disease (10.7 versus 11.3 events per 1000 person-years) and significantly raised major haemorrhage (8.6 versus 6.2)
  5. 5McNeil JJ, Nelson MR, Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi:10.1056/NEJMoa1803955. PMID 30221595.In the same trial, all-cause mortality was higher with aspirin (12.7 versus 11.1 per 1000 person-years), driven mainly by cancer deaths, a result the investigators called unexpected and to be interpreted with caution
  6. 6US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022 Apr 26;327(16):1577-1584. doi:10.1001/jama.2022.4983. PMID 35471505.The USPSTF recommends against initiating low-dose aspirin for primary prevention at age 60 or older, and makes it an individual decision at 40 to 59 only with a 10 percent or greater 10-year cardiovascular risk, noting the net benefit is small
  7. 7Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Apr 26;327(16):1585-1597. doi:10.1001/jama.2022.3337. PMID 35471507.Across 11 randomized trials of 134,470 people, low-dose aspirin gave small absolute reductions in major cardiovascular events (odds ratio 0.90) and small absolute increases in major bleeding (odds ratio 1.44), with no significant reduction in mortality

How this was made

Information, not medical advice. Every claim in this episode has a published source, listed above. It is not a substitute for advice about your own treatment — for that, talk to your doctor. Published 2026-10-19.